Ticker
$NRXP
1 catalyst touching NRXP in the last 60 days, newest first, each with the price move that followed.
- 62
NRx subsidiary awarded $11.2M DARPA contract for depression trial
NRx Defense, a subsidiary of NRXP, entered into a prime contract with DARPA valued at $11.2 million ($6.7M initially obligated) to conduct a clinical trial of NRX-101 combined with transcranial magnetic stimulation for treatment-resistant depression over 18 months. This is concrete funding for an FDA-approved clinical program, but at ~2–3% of typical biotech market cap for development-stage companies, the near-term impact is moderate unless it signals regulatory confidence or de-risks the program materially."
NRXP ▲SEC 8-K · 5 Oct 2026, 21:00 UTC
Information only. AURA does not give buy or sell recommendations.